APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibacterial (Drug) Resistance

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antibacterial (Drug) Resistance Industry Growth and Trends Forecast to 2032

22 December 2025123 pages

Choose your research edition.

Industry ResearchAntibacterial (Drug) Resistance Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibacterial (Drug) Resistance Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Antibacterial (Drug) Resistance Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibacterial (Drug) Resistance Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibacterial (Drug) Resistance Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Antibacterial (Drug) Resistance market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antibacterial (Drug) Resistance is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antibacterial (Drug) Resistance is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibacterial (Drug) Resistance is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antibacterial (Drug) Resistance include Merck, Pfizer, GSK, VenatoRx Pharmaceuticals, PENDOPHARM, Osel, Novexel, NanoSafe Coatings and Nabriva Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antibacterial (Drug) Resistance market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antibacterial (Drug) Resistance market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antibacterial (Drug) Resistance market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antibacterial (Drug) Resistance.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Antibacterial (Drug) Resistance market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antibacterial (Drug) Resistance Market by Company

Merck

Pfizer

GSK

VenatoRx Pharmaceuticals

PENDOPHARM

Osel

Novexel

NanoSafe Coatings

Nabriva Therapeutics

Morphochem

Microbecide

Melinta Therapeutics

Lyndra

Isis Pharmaceuticals

InterMune

Evolva Holding

Demuris

ContraFect

Cerexa

Aventis Pharma

Austell Laboratories

Assembly Biosciences

Arpida

ANTABIO

Allergan

Acino Holdings

Achaogen

Absynth Biologics

Abbott Laboratories

AAIPharma Services

Antibacterial (Drug) Resistance Segment by Type

Ceftolozane-Tazobactam (Zerbaxa)

Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)

Ceftaroline Fosamil (Teflaro/ Zinforo)

Ceftazidime-Avibactam (Avycaz/ Zavicefta)

Telavancin (Vibativ)

Tedizolid Phosphate (Sivextro)

PHASE III DRUGS

Dalbavancin (Dalvance/ Xydalba)

Oritavancin (Orbactiv/ Nuvocid)

Fidaxomicin (Dificid / Dificlir)

Antibacterial (Drug) Resistance Segment by Application

Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)

Blood Stream Infections (BSI)

Community Acquired Bacterial Pneumonia (CABP)

Clostridium Difficile Infections (CDI)

Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Complicated Urinary Tract Infection (CUTI)

Complicated Intra-Abdominal Infections (CIAI)

Antibacterial (Drug) Resistance Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibacterial (Drug) Resistance market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibacterial (Drug) Resistance and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibacterial (Drug) Resistance.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antibacterial (Drug) Resistance manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Antibacterial (Drug) Resistance in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Ceftolozane-Tazobactam (Zerbaxa) Table 2. Major Company of Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Table 3. Major Company of Ceftaroline Fosamil (Teflaro/ Zinforo) Table 4. Major Company of Ceftazidime-Avibactam (Avycaz/ Zavicefta) Table 5. Major Company of Telavancin (Vibativ) Table 6. Major Company of Tedizolid Phosphate (Sivextro) Table 7. Major Company of PHASE III DRUGS Table 8. Major Company of Dalbavancin (Dalvance/ Xydalba) Table 9. Major Company of Oritavancin (Orbactiv/ Nuvocid) Table 10. Major Company of Fidaxomicin (Dificid / Dificlir) Table 11. Global Antibacterial (Drug) Resistance Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 12. Global Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 13. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Type (2021-2026) Table 14. Global Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (US$ Million) Table 15. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Type (2021-2026) Table 16. Global Antibacterial (Drug) Resistance Price by Type (2021-2026) & (US$/unit) Table 17. Global Antibacterial (Drug) Resistance Sales by Type (2027-2032) & (k units) Table 18. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Type (2027-2032) Table 19. Global Antibacterial (Drug) Resistance Sales by Type (2027-2032) & (US$ Million) Table 20. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Type (2027-2032) Table 21. Global Antibacterial (Drug) Resistance Price by Type (2027-2032) & (US$/unit) Table 22. North America Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 23. North America Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (US$ Million) Table 24. Europe Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 25. Europe Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (US$ Million) Table 26. Asia-Pacific Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 27. Asia-Pacific Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (US$ Million) Table 28. Latin America Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 29. Latin America Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (US$ Million) Table 30. Middle East and Africa Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 31. Middle East and Africa Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (US$ Million) Table 32. Antibacterial (Drug) Resistance Industry Trends Table 33. Antibacterial (Drug) Resistance Industry Drivers Table 34. Antibacterial (Drug) Resistance Industry Opportunities and Challenges Table 35. Antibacterial (Drug) Resistance Industry Restraints Table 36. Global Antibacterial (Drug) Resistance Sales Revenue by Company (US$ Million) & (2021-2026) Table 37. Global Antibacterial (Drug) Resistance Revenue Market Share by Company (2021-2026) Table 38. Global Antibacterial (Drug) Resistance Sales by Company (2021-2026) & (k units) Table 39. Global Antibacterial (Drug) Resistance Sales Share by Company (2021-2026) Table 40. Global Antibacterial (Drug) Resistance Market Price by Company (2021-2026) & (US$/unit) Table 41. Global Antibacterial (Drug) Resistance Industry Company Ranking, 2024 VS 2025 VS 2026 Table 42. Global Antibacterial (Drug) Resistance Major Company Production Sites and Headquarters Table 43. Global Antibacterial (Drug) Resistance Company, Product Type & Application Table 44. Global Antibacterial (Drug) Resistance Company Establishment Date Table 45. Global Company Market Concentration Ratio (CR5 and HHI) Table 46. Global Antibacterial (Drug) Resistance by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 47. Global Antibacterial (Drug) Resistance Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 48. Global Antibacterial (Drug) Resistance Sales by Region (2021-2026) & (k units) Table 49. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Region (2021-2026) Table 50. Global Antibacterial (Drug) Resistance Sales by Region (2021-2026) & (US$ Million) Table 51. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Region (2021-2026) Table 52. Global Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 53. Global Antibacterial (Drug) Resistance Sales by Region (2027-2032) & (k units) Table 54. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Region (2027-2032) Table 55. Global Antibacterial (Drug) Resistance Sales by Region (2027-2032) & (US$ Million) Table 56. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Region (2027-2032) Table 57. Global Antibacterial (Drug) Resistance Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 58. Global Antibacterial (Drug) Resistance Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 59. Global Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 60. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Application (2021-2026) Table 61. Global Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (US$ Million) Table 62. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Application (2021-2026) Table 63. Global Antibacterial (Drug) Resistance Price by Application (2021-2026) & (US$/unit) Table 64. Global Antibacterial (Drug) Resistance Sales by Application (2027-2032) & (k units) Table 65. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Application (2027-2032) Table 66. Global Antibacterial (Drug) Resistance Sales by Application (2027-2032) & (US$ Million) Table 67. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Application (2027-2032) Table 68. Global Antibacterial (Drug) Resistance Price by Application (2027-2032) & (US$/unit) Table 69. North America Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 70. North America Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (US$ Million) Table 71. Europe Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 72. Europe Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (US$ Million) Table 73. Asia-Pacific Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 74. Asia-Pacific Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (US$ Million) Table 75. Latin America Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 76. Latin America Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (US$ Million) Table 77. Middle East and Africa Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 78. Middle East and Africa Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (US$ Million) Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Merck Antibacterial (Drug) Resistance Product Portfolio Table 83. Merck Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Pfizer Antibacterial (Drug) Resistance Product Portfolio Table 88. Pfizer Recent Development Table 89. GSK Company Information Table 90. GSK Business Overview Table 91. GSK Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. GSK Antibacterial (Drug) Resistance Product Portfolio Table 93. GSK Recent Development Table 94. VenatoRx Pharmaceuticals Company Information Table 95. VenatoRx Pharmaceuticals Business Overview Table 96. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio Table 98. VenatoRx Pharmaceuticals Recent Development Table 99. PENDOPHARM Company Information Table 100. PENDOPHARM Business Overview Table 101. PENDOPHARM Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio Table 103. PENDOPHARM Recent Development Table 104. Osel Company Information Table 105. Osel Business Overview Table 106. Osel Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Osel Antibacterial (Drug) Resistance Product Portfolio Table 108. Osel Recent Development Table 109. Novexel Company Information Table 110. Novexel Business Overview Table 111. Novexel Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Novexel Antibacterial (Drug) Resistance Product Portfolio Table 113. Novexel Recent Development Table 114. NanoSafe Coatings Company Information Table 115. NanoSafe Coatings Business Overview Table 116. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio Table 118. NanoSafe Coatings Recent Development Table 119. Nabriva Therapeutics Company Information Table 120. Nabriva Therapeutics Business Overview Table 121. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio Table 123. Nabriva Therapeutics Recent Development Table 124. Morphochem Company Information Table 125. Morphochem Business Overview Table 126. Morphochem Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Morphochem Antibacterial (Drug) Resistance Product Portfolio Table 128. Morphochem Recent Development Table 129. Microbecide Company Information Table 130. Microbecide Business Overview Table 131. Microbecide Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Microbecide Antibacterial (Drug) Resistance Product Portfolio Table 133. Microbecide Recent Development Table 134. Melinta Therapeutics Company Information Table 135. Melinta Therapeutics Business Overview Table 136. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio Table 138. Melinta Therapeutics Recent Development Table 139. Lyndra Company Information Table 140. Lyndra Business Overview Table 141. Lyndra Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Lyndra Antibacterial (Drug) Resistance Product Portfolio Table 143. Lyndra Recent Development Table 144. Isis Pharmaceuticals Company Information Table 145. Isis Pharmaceuticals Business Overview Table 146. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio Table 148. Isis Pharmaceuticals Recent Development Table 149. InterMune Company Information Table 150. InterMune Business Overview Table 151. InterMune Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. InterMune Antibacterial (Drug) Resistance Product Portfolio Table 153. InterMune Recent Development Table 154. Evolva Holding Company Information Table 155. Evolva Holding Business Overview Table 156. Evolva Holding Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 157. Evolva Holding Antibacterial (Drug) Resistance Product Portfolio Table 158. Evolva Holding Recent Development Table 159. Demuris Company Information Table 160. Demuris Business Overview Table 161. Demuris Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 162. Demuris Antibacterial (Drug) Resistance Product Portfolio Table 163. Demuris Recent Development Table 164. ContraFect Company Information Table 165. ContraFect Business Overview Table 166. ContraFect Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 167. ContraFect Antibacterial (Drug) Resistance Product Portfolio Table 168. ContraFect Recent Development Table 169. Cerexa Company Information Table 170. Cerexa Business Overview Table 171. Cerexa Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 172. Cerexa Antibacterial (Drug) Resistance Product Portfolio Table 173. Cerexa Recent Development Table 174. Aventis Pharma Company Information Table 175. Aventis Pharma Business Overview Table 176. Aventis Pharma Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 177. Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio Table 178. Aventis Pharma Recent Development Table 179. Austell Laboratories Company Information Table 180. Austell Laboratories Business Overview Table 181. Austell Laboratories Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 182. Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio Table 183. Austell Laboratories Recent Development Table 184. Assembly Biosciences Company Information Table 185. Assembly Biosciences Business Overview Table 186. Assembly Biosciences Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 187. Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio Table 188. Assembly Biosciences Recent Development Table 189. Arpida Company Information Table 190. Arpida Business Overview Table 191. Arpida Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 192. Arpida Antibacterial (Drug) Resistance Product Portfolio Table 193. Arpida Recent Development Table 194. ANTABIO Company Information Table 195. ANTABIO Business Overview Table 196. ANTABIO Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 197. ANTABIO Antibacterial (Drug) Resistance Product Portfolio Table 198. ANTABIO Recent Development Table 199. Allergan Company Information Table 200. Allergan Business Overview Table 201. Allergan Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 202. Allergan Antibacterial (Drug) Resistance Product Portfolio Table 203. Allergan Recent Development Table 204. Acino Holdings Company Information Table 205. Acino Holdings Business Overview Table 206. Acino Holdings Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 207. Acino Holdings Antibacterial (Drug) Resistance Product Portfolio Table 208. Acino Holdings Recent Development Table 209. Achaogen Company Information Table 210. Achaogen Business Overview Table 211. Achaogen Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 212. Achaogen Antibacterial (Drug) Resistance Product Portfolio Table 213. Achaogen Recent Development Table 214. Absynth Biologics Company Information Table 215. Absynth Biologics Business Overview Table 216. Absynth Biologics Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 217. Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio Table 218. Absynth Biologics Recent Development Table 219. Abbott Laboratories Company Information Table 220. Abbott Laboratories Business Overview Table 221. Abbott Laboratories Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 222. Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio Table 223. Abbott Laboratories Recent Development Table 224. AAIPharma Services Company Information Table 225. AAIPharma Services Business Overview Table 226. AAIPharma Services Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 227. AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio Table 228. AAIPharma Services Recent Development Table 229. North America Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 230. North America Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 231. North America Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2026) Table 232. North America Antibacterial (Drug) Resistance Sales Forecast by Country (2027-2032) & (k units) Table 233. North America Antibacterial (Drug) Resistance Sales Market Share Forecast by Country (2027-2032) Table 234. North America Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 235. North America Antibacterial (Drug) Resistance Market Size by Country (2021-2026) & (US$ Million) Table 236. North America Antibacterial (Drug) Resistance Market Share by Country (2021-2026) Table 237. North America Antibacterial (Drug) Resistance Market Size Forecast by Country (2027-2032) & (US$ Million) Table 238. North America Antibacterial (Drug) Resistance Market Share Forecast by Country (2027-2032) Table 239. Europe Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 240. Europe Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 241. Europe Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2026) Table 242. Europe Antibacterial (Drug) Resistance Sales Forecast by Country (2027-2032) & (k units) Table 243. Europe Antibacterial (Drug) Resistance Sales Market Share Forecast by Country (2027-2032) Table 244. Europe Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 245. Europe Antibacterial (Drug) Resistance Market Size by Country (2021-2026) & (US$ Million) Table 246. Europe Antibacterial (Drug) Resistance Market Share by Country (2021-2026) Table 247. Europe Antibacterial (Drug) Resistance Market Size Forecast by Country (2027-2032) & (US$ Million) Table 248. Europe Antibacterial (Drug) Resistance Market Share Forecast by Country (2027-2032) Table 249. Asia-Pacific Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 250. Asia-Pacific Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 251. Asia-Pacific Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2026) Table 252. Asia-Pacific Antibacterial (Drug) Resistance Sales Forecast by Country (2027-2032) & (k units) Table 253. Asia-Pacific Antibacterial (Drug) Resistance Sales Market Share Forecast by Country (2027-2032) Table 254. Asia-Pacific Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 255. Asia-Pacific Antibacterial (Drug) Resistance Market Size by Country (2021-2026) & (US$ Million) Table 256. Asia-Pacific Antibacterial (Drug) Resistance Market Share by Country (2021-2026) Table 257. Asia-Pacific Antibacterial (Drug) Resistance Market Size Forecast by Country (2027-2032) & (US$ Million) Table 258. Asia-Pacific Antibacterial (Drug) Resistance Market Share Forecast by Country (2027-2032) Table 259. Latin America Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 260. Latin America Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 261. Latin America Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2026) Table 262. Latin America Antibacterial (Drug) Resistance Sales Forecast by Country (2027-2032) & (k units) Table 263. Latin America Antibacterial (Drug) Resistance Sales Market Share Forecast by Country (2027-2032) Table 264. Latin America Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 265. Latin America Antibacterial (Drug) Resistance Market Size by Country (2021-2026) & (US$ Million) Table 266. Latin America Antibacterial (Drug) Resistance Market Share by Country (2021-2026) Table 267. Latin America Antibacterial (Drug) Resistance Market Size Forecast by Country (2027-2032) & (US$ Million) Table 268. Latin America Antibacterial (Drug) Resistance Market Share Forecast by Country (2027-2032) Table 269. Middle East and Africa Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 270. Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 271. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2026) Table 272. Middle East and Africa Antibacterial (Drug) Resistance Sales Forecast by Country (2027-2032) & (k units) Table 273. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share Forecast by Country (2027-2032) Table 274. Middle East and Africa Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 275. Middle East and Africa Antibacterial (Drug) Resistance Market Size by Country (2021-2026) & (US$ Million) Table 276. Middle East and Africa Antibacterial (Drug) Resistance Market Share by Country (2021-2026) Table 277. Middle East and Africa Antibacterial (Drug) Resistance Market Size Forecast by Country (2027-2032) & (US$ Million) Table 278. Middle East and Africa Antibacterial (Drug) Resistance Market Share Forecast by Country (2027-2032) Table 279. Key Raw Materials Table 280. Raw Materials Key Suppliers Table 281. Antibacterial (Drug) Resistance Distributors List Table 282. Antibacterial (Drug) Resistance Customers List Table 283. Research Programs/Design for This Report Table 284. Authors List of This Report Table 285. Secondary Sources Table 286. Primary Sources List of Figures Figure 1. Antibacterial (Drug) Resistance Image Figure 2. Global Antibacterial (Drug) Resistance Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibacterial (Drug) Resistance Market Size (2021-2032) & (US$ Million) Figure 4. Global Antibacterial (Drug) Resistance Sales (2021-2032) & (k units) Figure 5. Ceftolozane-Tazobactam (Zerbaxa) Image Figure 6. Global Ceftolozane-Tazobactam (Zerbaxa) Sales YoY Growth (2021-2032) & (k units) Figure 7. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Image Figure 8. Global Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Sales YoY Growth (2021-2032) & (k units) Figure 9. Ceftaroline Fosamil (Teflaro/ Zinforo) Image Figure 10. Global Ceftaroline Fosamil (Teflaro/ Zinforo) Sales YoY Growth (2021-2032) & (k units) Figure 11. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Image Figure 12. Global Ceftazidime-Avibactam (Avycaz/ Zavicefta) Sales YoY Growth (2021-2032) & (k units) Figure 13. Telavancin (Vibativ) Image Figure 14. Global Telavancin (Vibativ) Sales YoY Growth (2021-2032) & (k units) Figure 15. Tedizolid Phosphate (Sivextro) Image Figure 16. Global Tedizolid Phosphate (Sivextro) Sales YoY Growth (2021-2032) & (k units) Figure 17. PHASE III DRUGS Image Figure 18. Global PHASE III DRUGS Sales YoY Growth (2021-2032) & (k units) Figure 19. Dalbavancin (Dalvance/ Xydalba) Image Figure 20. Global Dalbavancin (Dalvance/ Xydalba) Sales YoY Growth (2021-2032) & (k units) Figure 21. Oritavancin (Orbactiv/ Nuvocid) Image Figure 22. Global Oritavancin (Orbactiv/ Nuvocid) Sales YoY Growth (2021-2032) & (k units) Figure 23. Fidaxomicin (Dificid / Dificlir) Image Figure 24. Global Fidaxomicin (Dificid / Dificlir) Sales YoY Growth (2021-2032) & (k units) Figure 25. Global Antibacterial (Drug) Resistance Market Size Overview by Type (2021-2032) & (US$ Million) Figure 26. Global Antibacterial (Drug) Resistance Market Share by Type 2025 VS 2032 Figure 27. North America Antibacterial (Drug) Resistance Sales Market Share in Volume by Type in 2025 Figure 28. North America Antibacterial (Drug) Resistance Sales Market Share in Value by Type in 2025 Figure 29. Europe Antibacterial (Drug) Resistance Sales Market Share in Volume by Type in 2025 Figure 30. Europe Antibacterial (Drug) Resistance Sales Market Share in Value by Type in 2025 Figure 31. Asia-Pacific Antibacterial (Drug) Resistance Sales Market Share in Volume by Type in 2025 Figure 32. Asia-Pacific Antibacterial (Drug) Resistance Sales Market Share in Value by Type in 2025 Figure 33. Latin America Antibacterial (Drug) Resistance Sales Market Share in Volume by Type in 2025 Figure 34. Latin America Antibacterial (Drug) Resistance Sales Market Share in Value by Type in 2025 Figure 35. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share in Volume by Type in 2025 Figure 36. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share in Value by Type in 2025 Figure 37. Global Top 5 and 10 Antibacterial (Drug) Resistance Players Market Share by Revenue in 2025 Figure 38. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 39. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) Image Figure 40. Global Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) Sales YoY Growth (2021-2032) & (k units) Figure 41. Blood Stream Infections (BSI) Image Figure 42. Global Blood Stream Infections (BSI) Sales YoY Growth (2021-2032) & (k units) Figure 43. Community Acquired Bacterial Pneumonia (CABP) Image Figure 44. Global Community Acquired Bacterial Pneumonia (CABP) Sales YoY Growth (2021-2032) & (k units) Figure 45. Clostridium Difficile Infections (CDI) Image Figure 46. Global Clostridium Difficile Infections (CDI) Sales YoY Growth (2021-2032) & (k units) Figure 47. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Image Figure 48. Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Sales YoY Growth (2021-2032) & (k units) Figure 49. Complicated Urinary Tract Infection (CUTI) Image Figure 50. Global Complicated Urinary Tract Infection (CUTI) Sales YoY Growth (2021-2032) & (k units) Figure 51. Complicated Intra-Abdominal Infections (CIAI) Image Figure 52. Global Complicated Intra-Abdominal Infections (CIAI) Sales YoY Growth (2021-2032) & (k units) Figure 53. Global Antibacterial (Drug) Resistance Market Size Overview by Application (2021-2032) & (US$ Million) Figure 54. Global Antibacterial (Drug) Resistance Market Share by Application 2025 VS 2032 Figure 55. North America Antibacterial (Drug) Resistance Sales Market Share in Volume by Application in 2025 Figure 56. North America Antibacterial (Drug) Resistance Sales Market Share in Value by Application in 2025 Figure 57. Europe Antibacterial (Drug) Resistance Sales Market Share in Volume by Application in 2025 Figure 58. Europe Antibacterial (Drug) Resistance Sales Market Share in Value by Application in 2025 Figure 59. Asia-Pacific Antibacterial (Drug) Resistance Sales Market Share in Volume by Application in 2025 Figure 60. Asia-Pacific Antibacterial (Drug) Resistance Sales Market Share in Value by Application in 2025 Figure 61. Latin America Antibacterial (Drug) Resistance Sales Market Share in Volume by Application in 2025 Figure 62. Latin America Antibacterial (Drug) Resistance Sales Market Share in Value by Application in 2025 Figure 63. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share in Volume by Application in 2025 Figure 64. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share in Value by Application in 2025 Figure 65. North America Antibacterial (Drug) Resistance Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 66. North America Antibacterial (Drug) Resistance Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. North America Antibacterial (Drug) Resistance Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. North America Antibacterial (Drug) Resistance Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Europe Antibacterial (Drug) Resistance Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 70. Europe Antibacterial (Drug) Resistance Sales Share by Country: 2021 VS 2025 VS 2032 Figure 71. Europe Antibacterial (Drug) Resistance Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 72. Europe Antibacterial (Drug) Resistance Market Share by Country: 2021 VS 2025 VS 2032 Figure 73. Asia-Pacific Antibacterial (Drug) Resistance Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 74. Asia-Pacific Antibacterial (Drug) Resistance Sales Share by Country: 2021 VS 2025 VS 2032 Figure 75. Asia-Pacific Antibacterial (Drug) Resistance Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 76. Asia-Pacific Antibacterial (Drug) Resistance Market Share by Country: 2021 VS 2025 VS 2032 Figure 77. Latin America Antibacterial (Drug) Resistance Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 78. Latin America Antibacterial (Drug) Resistance Sales Share by Country: 2021 VS 2025 VS 2032 Figure 79. Latin America Antibacterial (Drug) Resistance Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 80. Latin America Antibacterial (Drug) Resistance Market Share by Country: 2021 VS 2025 VS 2032 Figure 81. Middle East and Africa Antibacterial (Drug) Resistance Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 82. Middle East and Africa Antibacterial (Drug) Resistance Sales Share by Country: 2021 VS 2025 VS 2032 Figure 83. Middle East and Africa Antibacterial (Drug) Resistance Market Size by Country: 2021 VS 2025 VS 2032 (US$

Scope & coverage.

Types
  • Ceftolozane-Tazobactam (Zerbaxa)
  • Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  • Ceftaroline Fosamil (Teflaro/ Zinforo)
  • Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  • Telavancin (Vibativ)
  • Tedizolid Phosphate (Sivextro)
  • PHASE III DRUGS
  • Dalbavancin (Dalvance/ Xydalba)
  • Oritavancin (Orbactiv/ Nuvocid)
  • Fidaxomicin (Dificid / Dificlir)
Applications
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • Blood Stream Infections (BSI)
  • Community Acquired Bacterial Pneumonia (CABP)
  • Clostridium Difficile Infections (CDI)
  • Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  • Complicated Urinary Tract Infection (CUTI)
  • Complicated Intra-Abdominal Infections (CIAI)
Companies covered
  • Merck
  • Pfizer
  • GSK
  • VenatoRx Pharmaceuticals
  • PENDOPHARM
  • Osel
  • Novexel
  • NanoSafe Coatings
  • Nabriva Therapeutics
  • Morphochem
  • Microbecide
  • Melinta Therapeutics
  • Lyndra
  • Isis Pharmaceuticals
  • InterMune
  • Evolva Holding
  • Demuris
  • ContraFect
  • Cerexa
  • Aventis Pharma
  • Austell Laboratories
  • Assembly Biosciences
  • Arpida
  • ANTABIO
  • Allergan
  • Acino Holdings
  • Achaogen
  • Absynth Biologics
  • Abbott Laboratories
  • AAIPharma Services

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antibacterial (Drug) Resistance Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Antibacterial (Drug) Resistance Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Antibacterial (Drug) Resistance Market by Type
  6. 1.3.1 Ceftolozane-Tazobactam (Zerbaxa)
  7. 1.3.2 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  8. 1.3.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
  9. 1.3.4 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  10. 1.3.5 Telavancin (Vibativ)
  11. 1.3.6 Tedizolid Phosphate (Sivextro)
  12. 1.3.7 PHASE III DRUGS
  13. 1.3.8 Dalbavancin (Dalvance/ Xydalba)
  14. 1.3.9 Oritavancin (Orbactiv/ Nuvocid)
  15. 1.3.10 Fidaxomicin (Dificid / Dificlir)
  16. 1.4 Global Antibacterial (Drug) Resistance Market Size by Type
  17. 1.4.1 Global Antibacterial (Drug) Resistance Market Size Overview by Type (2021-2032)
  18. 1.4.2 Global Antibacterial (Drug) Resistance Historic Market Size Review by Type (2021-2026)
  19. 1.4.3 Global Antibacterial (Drug) Resistance Forecasted Market Size by Type (2027-2032)
  20. 1.5 Key Regions Market Size by Type
  21. 1.5.1 North America Antibacterial (Drug) Resistance Sales Breakdown by Type (2021-2026)
  22. 1.5.2 Europe Antibacterial (Drug) Resistance Sales Breakdown by Type (2021-2026)
  23. 1.5.3 Asia-Pacific Antibacterial (Drug) Resistance Sales Breakdown by Type (2021-2026)
  24. 1.5.4 South America Antibacterial (Drug) Resistance Sales Breakdown by Type (2021-2026)
  25. 1.5.5 Middle East and Africa Antibacterial (Drug) Resistance Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Antibacterial (Drug) Resistance Industry Trends
  2. 2.2 Antibacterial (Drug) Resistance Industry Drivers
  3. 2.3 Antibacterial (Drug) Resistance Industry Opportunities and Challenges
  4. 2.4 Antibacterial (Drug) Resistance Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Antibacterial (Drug) Resistance Revenue (2021-2026)
  2. 3.2 Global Top Players by Antibacterial (Drug) Resistance Sales (2021-2026)
  3. 3.3 Global Top Players by Antibacterial (Drug) Resistance Price (2021-2026)
  4. 3.4 Global Antibacterial (Drug) Resistance Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antibacterial (Drug) Resistance Major Company Production Sites & Headquarters
  6. 3.6 Global Antibacterial (Drug) Resistance Company, Product Type & Application
  7. 3.7 Global Antibacterial (Drug) Resistance Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antibacterial (Drug) Resistance Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antibacterial (Drug) Resistance Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antibacterial (Drug) Resistance Tier 1, Tier 2, and Tier 3
4 Antibacterial (Drug) Resistance Regional Status and Outlook
  1. 4.1 Global Antibacterial (Drug) Resistance Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Antibacterial (Drug) Resistance Historic Market Size by Region
  3. 4.2.1 Global Antibacterial (Drug) Resistance Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Antibacterial (Drug) Resistance Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Antibacterial (Drug) Resistance Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Antibacterial (Drug) Resistance Forecasted Market Size by Region
  7. 4.3.1 Global Antibacterial (Drug) Resistance Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Antibacterial (Drug) Resistance Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Antibacterial (Drug) Resistance Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antibacterial (Drug) Resistance by Application
  1. 5.1 Antibacterial (Drug) Resistance Market by Application
  2. 5.1.1 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  3. 5.1.2 Blood Stream Infections (BSI)
  4. 5.1.3 Community Acquired Bacterial Pneumonia (CABP)
  5. 5.1.4 Clostridium Difficile Infections (CDI)
  6. 5.1.5 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  7. 5.1.6 Complicated Urinary Tract Infection (CUTI)
  8. 5.1.7 Complicated Intra-Abdominal Infections (CIAI)
  9. 5.2 Global Antibacterial (Drug) Resistance Market Size by Application
  10. 5.2.1 Global Antibacterial (Drug) Resistance Market Size Overview by Application (2021-2032)
  11. 5.2.2 Global Antibacterial (Drug) Resistance Historic Market Size Review by Application (2021-2026)
  12. 5.2.3 Global Antibacterial (Drug) Resistance Forecasted Market Size by Application (2027-2032)
  13. 5.3 Key Regions Market Size by Application
  14. 5.3.1 North America Antibacterial (Drug) Resistance Sales Breakdown by Application (2021-2026)
  15. 5.3.2 Europe Antibacterial (Drug) Resistance Sales Breakdown by Application (2021-2026)
  16. 5.3.3 Asia-Pacific Antibacterial (Drug) Resistance Sales Breakdown by Application (2021-2026)
  17. 5.3.4 South America Antibacterial (Drug) Resistance Sales Breakdown by Application (2021-2026)
  18. 5.3.5 Middle East and Africa Antibacterial (Drug) Resistance Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Merck
  2. 6.1.1 Merck Company Information
  3. 6.1.2 Merck Business Overview
  4. 6.1.3 Merck Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Merck Antibacterial (Drug) Resistance Product Portfolio
  6. 6.1.5 Merck Recent Developments
  7. 6.2 Pfizer
  8. 6.2.1 Pfizer Company Information
  9. 6.2.2 Pfizer Business Overview
  10. 6.2.3 Pfizer Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Pfizer Antibacterial (Drug) Resistance Product Portfolio
  12. 6.2.5 Pfizer Recent Developments
  13. 6.3 GSK
  14. 6.3.1 GSK Company Information
  15. 6.3.2 GSK Business Overview
  16. 6.3.3 GSK Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 GSK Antibacterial (Drug) Resistance Product Portfolio
  18. 6.3.5 GSK Recent Developments
  19. 6.4 VenatoRx Pharmaceuticals
  20. 6.4.1 VenatoRx Pharmaceuticals Company Information
  21. 6.4.2 VenatoRx Pharmaceuticals Business Overview
  22. 6.4.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
  24. 6.4.5 VenatoRx Pharmaceuticals Recent Developments
  25. 6.5 PENDOPHARM
  26. 6.5.1 PENDOPHARM Company Information
  27. 6.5.2 PENDOPHARM Business Overview
  28. 6.5.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio
  30. 6.5.5 PENDOPHARM Recent Developments
  31. 6.6 Osel
  32. 6.6.1 Osel Company Information
  33. 6.6.2 Osel Business Overview
  34. 6.6.3 Osel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Osel Antibacterial (Drug) Resistance Product Portfolio
  36. 6.6.5 Osel Recent Developments
  37. 6.7 Novexel
  38. 6.7.1 Novexel Company Information
  39. 6.7.2 Novexel Business Overview
  40. 6.7.3 Novexel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Novexel Antibacterial (Drug) Resistance Product Portfolio
  42. 6.7.5 Novexel Recent Developments
  43. 6.8 NanoSafe Coatings
  44. 6.8.1 NanoSafe Coatings Company Information
  45. 6.8.2 NanoSafe Coatings Business Overview
  46. 6.8.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio
  48. 6.8.5 NanoSafe Coatings Recent Developments
  49. 6.9 Nabriva Therapeutics
  50. 6.9.1 Nabriva Therapeutics Company Information
  51. 6.9.2 Nabriva Therapeutics Business Overview
  52. 6.9.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio
  54. 6.9.5 Nabriva Therapeutics Recent Developments
  55. 6.10 Morphochem
  56. 6.10.1 Morphochem Company Information
  57. 6.10.2 Morphochem Business Overview
  58. 6.10.3 Morphochem Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Morphochem Antibacterial (Drug) Resistance Product Portfolio
  60. 6.10.5 Morphochem Recent Developments
  61. 6.11 Microbecide
  62. 6.11.1 Microbecide Company Information
  63. 6.11.2 Microbecide Business Overview
  64. 6.11.3 Microbecide Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Microbecide Antibacterial (Drug) Resistance Product Portfolio
  66. 6.11.5 Microbecide Recent Developments
  67. 6.12 Melinta Therapeutics
  68. 6.12.1 Melinta Therapeutics Company Information
  69. 6.12.2 Melinta Therapeutics Business Overview
  70. 6.12.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio
  72. 6.12.5 Melinta Therapeutics Recent Developments
  73. 6.13 Lyndra
  74. 6.13.1 Lyndra Company Information
  75. 6.13.2 Lyndra Business Overview
  76. 6.13.3 Lyndra Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Lyndra Antibacterial (Drug) Resistance Product Portfolio
  78. 6.13.5 Lyndra Recent Developments
  79. 6.14 Isis Pharmaceuticals
  80. 6.14.1 Isis Pharmaceuticals Company Information
  81. 6.14.2 Isis Pharmaceuticals Business Overview
  82. 6.14.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
  84. 6.14.5 Isis Pharmaceuticals Recent Developments
  85. 6.15 InterMune
  86. 6.15.1 InterMune Company Information
  87. 6.15.2 InterMune Business Overview
  88. 6.15.3 InterMune Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 InterMune Antibacterial (Drug) Resistance Product Portfolio
  90. 6.15.5 InterMune Recent Developments
  91. 6.16 Evolva Holding
  92. 6.16.1 Evolva Holding Company Information
  93. 6.16.2 Evolva Holding Business Overview
  94. 6.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Evolva Holding Antibacterial (Drug) Resistance Product Portfolio
  96. 6.16.5 Evolva Holding Recent Developments
  97. 6.17 Demuris
  98. 6.17.1 Demuris Company Information
  99. 6.17.2 Demuris Business Overview
  100. 6.17.3 Demuris Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Demuris Antibacterial (Drug) Resistance Product Portfolio
  102. 6.17.5 Demuris Recent Developments
  103. 6.18 ContraFect
  104. 6.18.1 ContraFect Company Information
  105. 6.18.2 ContraFect Business Overview
  106. 6.18.3 ContraFect Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 ContraFect Antibacterial (Drug) Resistance Product Portfolio
  108. 6.18.5 ContraFect Recent Developments
  109. 6.19 Cerexa
  110. 6.19.1 Cerexa Company Information
  111. 6.19.2 Cerexa Business Overview
  112. 6.19.3 Cerexa Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Cerexa Antibacterial (Drug) Resistance Product Portfolio
  114. 6.19.5 Cerexa Recent Developments
  115. 6.20 Aventis Pharma
  116. 6.20.1 Aventis Pharma Company Information
  117. 6.20.2 Aventis Pharma Business Overview
  118. 6.20.3 Aventis Pharma Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio
  120. 6.20.5 Aventis Pharma Recent Developments
  121. 6.21 Austell Laboratories
  122. 6.21.1 Austell Laboratories Company Information
  123. 6.21.2 Austell Laboratories Business Overview
  124. 6.21.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio
  126. 6.21.5 Austell Laboratories Recent Developments
  127. 6.22 Assembly Biosciences
  128. 6.22.1 Assembly Biosciences Company Information
  129. 6.22.2 Assembly Biosciences Business Overview
  130. 6.22.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio
  132. 6.22.5 Assembly Biosciences Recent Developments
  133. 6.23 Arpida
  134. 6.23.1 Arpida Company Information
  135. 6.23.2 Arpida Business Overview
  136. 6.23.3 Arpida Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Arpida Antibacterial (Drug) Resistance Product Portfolio
  138. 6.23.5 Arpida Recent Developments
  139. 6.24 ANTABIO
  140. 6.24.1 ANTABIO Company Information
  141. 6.24.2 ANTABIO Business Overview
  142. 6.24.3 ANTABIO Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 ANTABIO Antibacterial (Drug) Resistance Product Portfolio
  144. 6.24.5 ANTABIO Recent Developments
  145. 6.25 Allergan
  146. 6.25.1 Allergan Company Information
  147. 6.25.2 Allergan Business Overview
  148. 6.25.3 Allergan Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Allergan Antibacterial (Drug) Resistance Product Portfolio
  150. 6.25.5 Allergan Recent Developments
  151. 6.26 Acino Holdings
  152. 6.26.1 Acino Holdings Company Information
  153. 6.26.2 Acino Holdings Business Overview
  154. 6.26.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Acino Holdings Antibacterial (Drug) Resistance Product Portfolio
  156. 6.26.5 Acino Holdings Recent Developments
  157. 6.27 Achaogen
  158. 6.27.1 Achaogen Company Information
  159. 6.27.2 Achaogen Business Overview
  160. 6.27.3 Achaogen Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  161. 6.27.4 Achaogen Antibacterial (Drug) Resistance Product Portfolio
  162. 6.27.5 Achaogen Recent Developments
  163. 6.28 Absynth Biologics
  164. 6.28.1 Absynth Biologics Company Information
  165. 6.28.2 Absynth Biologics Business Overview
  166. 6.28.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  167. 6.28.4 Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio
  168. 6.28.5 Absynth Biologics Recent Developments
  169. 6.29 Abbott Laboratories
  170. 6.29.1 Abbott Laboratories Company Information
  171. 6.29.2 Abbott Laboratories Business Overview
  172. 6.29.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  173. 6.29.4 Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio
  174. 6.29.5 Abbott Laboratories Recent Developments
  175. 6.30 AAIPharma Services
  176. 6.30.1 AAIPharma Services Company Information
  177. 6.30.2 AAIPharma Services Business Overview
  178. 6.30.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2021-2026)
  179. 6.30.4 AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio
  180. 6.30.5 AAIPharma Services Recent Developments
7 North America by Country
  1. 7.1 North America Antibacterial (Drug) Resistance Sales by Country
  2. 7.1.1 North America Antibacterial (Drug) Resistance Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Antibacterial (Drug) Resistance Sales by Country (2021-2026)
  4. 7.1.3 North America Antibacterial (Drug) Resistance Sales Forecast by Country (2027-2032)
  5. 7.2 North America Antibacterial (Drug) Resistance Market Size by Country
  6. 7.2.1 North America Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Antibacterial (Drug) Resistance Market Size by Country (2021-2026)
  8. 7.2.3 North America Antibacterial (Drug) Resistance Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Antibacterial (Drug) Resistance Sales by Country
  2. 8.1.1 Europe Antibacterial (Drug) Resistance Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Antibacterial (Drug) Resistance Sales by Country (2021-2026)
  4. 8.1.3 Europe Antibacterial (Drug) Resistance Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Antibacterial (Drug) Resistance Market Size by Country
  6. 8.2.1 Europe Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Antibacterial (Drug) Resistance Market Size by Country (2021-2026)
  8. 8.2.3 Europe Antibacterial (Drug) Resistance Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Antibacterial (Drug) Resistance Sales by Country
  2. 9.1.1 Asia-Pacific Antibacterial (Drug) Resistance Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Antibacterial (Drug) Resistance Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Antibacterial (Drug) Resistance Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Antibacterial (Drug) Resistance Market Size by Country
  6. 9.2.1 Asia-Pacific Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Antibacterial (Drug) Resistance Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Antibacterial (Drug) Resistance Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Antibacterial (Drug) Resistance Sales by Country
  2. 10.1.1 South America Antibacterial (Drug) Resistance Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Antibacterial (Drug) Resistance Sales by Country (2021-2026)
  4. 10.1.3 South America Antibacterial (Drug) Resistance Sales Forecast by Country (2027-2032)
  5. 10.2 South America Antibacterial (Drug) Resistance Market Size by Country
  6. 10.2.1 South America Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Antibacterial (Drug) Resistance Market Size by Country (2021-2026)
  8. 10.2.3 South America Antibacterial (Drug) Resistance Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country
  2. 11.1.1 Middle East and Africa Antibacterial (Drug) Resistance Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Antibacterial (Drug) Resistance Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Antibacterial (Drug) Resistance Market Size by Country
  6. 11.2.1 Middle East and Africa Antibacterial (Drug) Resistance Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Antibacterial (Drug) Resistance Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Antibacterial (Drug) Resistance Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Antibacterial (Drug) Resistance Value Chain Analysis
  2. 12.1.1 Antibacterial (Drug) Resistance Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Antibacterial (Drug) Resistance Production Mode & Process
  7. 12.2 Antibacterial (Drug) Resistance Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Antibacterial (Drug) Resistance Distributors
  10. 12.2.3 Antibacterial (Drug) Resistance Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst